Table 1.
Patient Characteristics of Anti-TNF Usersa
| Characteristics | Intravenous anti-TNF users, N (%) (N = 202) | Subcutaneous anti-TNF users, N (%) (N = 298) | P value |
|---|---|---|---|
| Age, yrs | <.001 | ||
| 18–39 | 62 (30.7) | 64 (21.5) | |
| 40–64 | 107 (53) | 218 (73.2) | |
| ≥65 | 33 (16.3) | 16 (5.4) | |
| Mean | 49.8 (16) | 49.4 (12.2) | .761 |
| Sex | .606 | ||
| Female | 140 (69.3) | 200 (67.1) | |
| Male | 62 (30.7) | 98 (32.9) | |
| Education | .736 | ||
| High school graduate/equivalent or less | 53 (0.3) | 65 (0.2) | |
| Some college, technical school, or trade school, but no degree | 37 (18.3) | 57 (19.1) | |
| Completed technical or community college | 25 (12.4) | 37 (12.4) | |
| College/university degree or higher | 87 (43.1) | 138 (46.3) | |
| Race | |||
| White | 185 (91.6) | 279 (93.6) | .387 |
| Other | 17 (8.4) | 19 (6.4) | |
| Ethnicity | |||
| Hispanic or Latino | 9 (4.5) | 8 (2.7) | .284 |
| Total household income in the past 12 mo | .083 | ||
| <$50,000 | 87 (43.1) | 101 (33.9) | |
| $50,000–$100,000 | 68 (33.7) | 119 (39.9) | |
| >$100,000 | 33 (16.3) | 64 (21.5) | |
| Current employment status | .039 | ||
| Employed full time outside the home | 97 (48) | 177 (59.4) | |
| Employed part time outside the home, full-time homemaker, or full-/part-time student | 40 (19.8) | 54 (18.1) | |
| Disabled, retired, unemployed | 64 (31.7) | 67 (22.5) | |
| Experience with anti-TNF agents | |||
| Current anti-TNF medication use | |||
| Infliximab | 202 (100) | ||
| Certolizumab pegol | 24 (8.1) | ||
| Adalimumab | 140 (47) | ||
| Etanercept | 125 (42) | ||
| Golimumab | 9 (3) | ||
| Indication | |||
| Crohn's disease | 78 (38.6) | 77 (25.8) | .004 |
| Rheumatoid arthritis | 92 (45.5) | 151 (50.7) | .007 |
| Plaque psoriasis | 12 (5.9) | 50 (16.8) | .001 |
| Psoriatic arthritis | 23 (11.4) | 50 (16.8) | .076 |
| Ankylosing spondylitis | 15 (7.4) | 17 (5.7) | .191 |
| Others | 15 (7.4) | 14 (4.7) | .200 |
| Duration of current anti-TNF therapy | .011 | ||
| <2 mo | 1 (0.5) | 6 (2) | |
| 2 mo to <6 mo | 5 (2.5) | 25 (8.4) | |
| 6 mo to <1 yr | 26 (12.9) | 44 (14.8) | |
| >1 yr | 170 (84.2) | 223 (74.8) | |
| Previous anti-TNF medication use | |||
| Intravenous (infliximab) | |||
| Yes | 61 (20.5) | ||
| No | 236 (79.2) | ||
| Subcutaneous (adalimumab, certolizumab pegol, etanercept, golimumab) | .133 | ||
| Yes | 48 (23.8) | 73 (24.5) | |
| No | 151 (74.8) | 225 (75.5) |
a
Numbers may not add to totals because missing values are not reported.
TNF indicates tumor necrosis factor.